The challenge of cutaneous adverse drug reactions for the consultant dermatologist is in determining a specific etiologic agent, especially in the setting of polypharmacy. The risk of reexposure to individual medications usually outweighs the benefits, especially in the case of severe drug eruptions. Recently, patch testing has been advocated as a potentially useful test in some severe cutaneous adverse drug reactions, especially acute generalized exanthematous pustulosis (AGEP).1
Watsky KL. Acute Generalized Exanthematous Pustulosis Induced by Metronidazole: The Role of Patch Testing. Arch Dermatol. 1999;135(1):93–94. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-1-dlt0199
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: